Pembrolizumab plus gut microbiome changes after pancreatic chemo
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This Phase 2 study tests whether changing the gut microbiome (the gut’s helpful bacteria) and giving pembrolizumab after chemotherapy can improve outcomes for people with operable pancreatic cancer. It aims to see if this approach can boost the immune system after standard treatment and help reduce cancer returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have pancreatic adenocarcinoma confirmed by pathology (not other or mixed tumor types).
- Your scans must show resectable (operable) stage T1–3, no distant spread (M0) and limited lymph node spread (N0–2), based on detailed CT blood-vessel imaging.
- You must be able and willing to have biopsies before treatment, during treatment, and then have the cancer surgically removed.
- You must be age 18 or older, with good activity level (ECOG 0–1).
- Your blood tests must be adequate (white blood cells, platelets, and hemoglobin) and liver/kidney clotting tests must be within allowed limits.
- You must not have certain conditions like autoimmune disease needing immune-suppressing medicines, active infections, or lung disease that could worsen with treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of standard chemotherapy, MRI-guided radiation, and surgery for people with locally advanced pancreatic cancer that might be removable. The goal is to see if this approach can make more tumors resectable.
This trial uses a special gene test on fluid taken from an endoscopic ultrasound (EUS) biopsy to help choose chemotherapy before surgery for pancreas cancer. It aims to see if this approach improves outcomes by matching treatment to the tumor’s RNA pattern.
This trial tests a combination of an immunotherapy drug (adebrelimab) with chemotherapy before surgery for pancreatic cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.